Document is current
Any future updates will be listed below
-
Authors
Freitas-Cortez, Maria Angelica
Masrorpour, Fatemeh
Jiang, Hong
Mahmud, Iqbal
Lu, Yue
Huang, Ailing
Duong, Lisa K.
Wang, Qi
Voss, Tiffany A.
Kettlun Leyton, Claudia S.
Wei, Bo
Chan, Wai-Kin
Lin, Kevin
Zhang, Jie
Tsouko, Efrosini
Ganjoo, Shonik
Barsoumian, Hampartsoum B.
Riad, Thomas S.
Hu, Yun
Leuschner, Carola
Puebla-Osorio, Nahum
Wang, Jing
Hu, Jian
Davies, Michael A.
Puduvalli, Vinay K.
Billon, Cyrielle
Burris, Thomas P.
Lorenzi, Philip L.
Gan, Boyi
Welsh, James W.
- License Information
-
More Information
Article History
Received: 4 June 2024
Accepted: 11 December 2024
First Online: 3 February 2025
Declarations
:
: M.A.F.C. and J.W.W. has pending patent on a small molecule targeting Fabp7. J.W.W. is supported by Alkermes (Research grant), Nanobiotix (Research grant, Travel expenses, SAB), GSK (Research grant), BMS (Research grant), Merck (Research grant), Varian (Research grant, Travel expenses, clinical sponsored research), Checkmate Pharmaceuticals (Research grant, SAB), Reflexion (Research grant, Travel expenses, Stock options, SAB), Artidis (research grants, clinical sponsored research), Takeda (Research grant), Hotspot Therapeutics (Research grant), Gilead (Research grant), Kiromic (Research grant), Bayer Health (Research grant), Agenus (SAB), Novocure (SAB), Alpine Immune Science (SAB, stock options), Oncoresponse (SAB, stock options), Astra Zeneca (consultant), Nanorobotix (stock options), GI innovation (consultant), Molecular Match (Stock options, consultant), Kezar Life Science (SAB). M.A.D. has been a consultant to Roche/Genentech, Array, Pfizer, Novartis, BMS, GSK, Sanofi-Aventis, Vaccinex, Apexigen, Eisai, Iovance, Merck, and ABM Therapeutics, and he has been the PI of research grants to MD Anderson by Roche/Genentech, GSK, Sanofi-Aventis, Merck, Myriad, Oncothyreon, Pfizer, ABM Therapeutics, and LEAD Pharma. All other authors have no conflict of interest to declare.
